Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors

OBJECTIVE: To determine whether changes in standard and novel risk factors during the ACT NOW trial explained the slower rate of CIMT progression with pioglitazone treatment in persons with prediabetes. METHODS AND RESULTS: CIMT was measured in 382 participants at the beginning and up to three addit...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Saremi, Aramesh, Schwenke, Dawn C., Buchanan, Thomas A., Hodis, Howard N., Mack, Wendy J., Banerji, MaryAnn, Bray, George A., Clement, Stephen C., Henry, Robert R., Kitabchi, Abbas E., Mudaliar, Sunder, Ratner, Robert E., Stentz, Frankie B., Musi, Nicolas, Tripathy, Devjit, DeFronzo, Ralph A., Reaven, Peter D.
Formato: Artigo
Idioma:Inglês
Publicado em: 2012
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3908828/
https://ncbi.nlm.nih.gov/pubmed/23175674
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/ATVBAHA.112.300346
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados